BP/2 BIOZZI Mouse Spontaneous Asthmatic Model
Mutant inbred mouse
INSERM, Unit 255 (Curie Institute, Paris, France) - 1994
Colour and related genotype:
albino mouse - Tyrc/Tyrc MHC: Haplotype H2q
Easy to rear
Description of our model and application areas
High antibody responder descended from selection done by BIOZZI and COL. The selection for high antibody titer, following a challenge with sheep erythrocytes started in 1968, from outbred SWISS stock. The strain has been bred in a small population for 67 generations.
In mice, 3 loci that influence asthma traits have been identified: the Asthm1 locus (chromosome 9), the Asthm2 locus (chromosome 11) and a locus on chromosome 17 near Bhr3 (Zhang et al., 1999).
In the BP/2 model, an immunization and subsequent challenge with ovalbumin results in asthma symptoms, similar to the ones seen in human allergic asthma: airway inflammation, eosinophil infiltration and non-specific bronchial responsiveness. The locus associated with this respiratory system response is Asthm2. The strain has a high IgE titre and expresses bronchopulmonary hyperresponsiveness (BHR) after an antigenic challenge. BHR is accompanied by airway sequestration of lymphocytes and eosinophils, and by IgE-bearing granulocytes / basophils. After antigen administration, BP2 mice respond with an anaphylactic shock characterized by an intense serotonin-dependent bronchoconstriction, with probable mast cell activation. Immunised and multi-challenged BP2 mice become hyperresponsive to bronchoconstrictor agents, including
serotonin, acetylcholine or methacholine. This hyperreactivity lasts several days and probably has an inflammatory etiology because it is suppressed by dexamethasone. Dex also prevents eosinophilia of the airways and production of broncho-alveolar liquid. The airways of BP/2 mice do not respond to exogenous nor endogenous histamine. Isolated airways of BP2 mice contract upon exposure to antigen, to serotonin and cholinergic agents, which correlates in vivo and in vitro results.
Protective effects of drugs can be targeted insofar as citokyne concentration in the blood, peritoneum and bronchoalveolar fluid can be known after allergenic challenge. Interleukine 5 and TNF-a releases have notably been demonstrated.
Main application and research fields
Download the technical sheet
You may also be interested in these models
Warning: Illegal string offset 'title' in /home/deca3005/janvier-labs.com/html/wp-content/themes/oceanwp-child-theme-master/single-fiche_produit.php on line 921
Voir tous les modèles de recherche